EUVIMEDScopri EUVIMED
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open access · CC BY 4.0

The safety and efficacy of total mesorectal excision ( TME ) surgery following dose‐escalation: Surgical outcomes from the organ preservation in early rectal adenocarcinoma ( OPERA ) trial, a European multicentre phase 3 randomised trial ( NCT02505750 )

Arthur Sun Myint iD, Christopher Rao, Nicolas Barbet, Brice Thamphya, Tanguy Pace-Loscos, Renaud Schiappa, Nicolas Magné, Isabelle Martel-Lafay, Laurent Mineur, Melanie Deberne, Thomas Zilli, Amandeep Dhadda and 1 more

Colorectal Disease · 2023

DOI: 10.1111/codi.16773 ↗

At a glance

Randomisierte kontrollierte Studie in Colorectal Disease, 2023. Written by Arthur Sun Myint and 12 co-authors. Institution: Clatterbridge Cancer Centre, Liverpool, UK. Major MEDLINE topics: Rectal Neoplasms, Adenocarcinoma. Cited 8 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Aim

Nonsurgical treatment with chemoradiotherapy for rectal cancer is gaining interest as it avoids total mesorectal excision (TME) surgery and stoma. The OPERA trial aims to evaluate whether dose escalation with contact X‐ray brachytherapy (CXB) boost improves organ preservation compared to external beam radiotherapy (EBRT) boost. It has been suggested that dose escalation adversely affects surgical outcomes and therefore we report outcomes following TME in OPERA at 36 months.

Methods

OPERA is a European multicentre phase 3 trial (NCT02505750) which randomises patients with cT2‐3a‐b, cN0‐1, M0 to EBCRT (45 Gy in 25 fractions over 5 weeks with oral capecitabine 825 mg/m 2 ) followed by EBRT boost (9 Gy in 5 fractions over 5 days) versus EBCRT followed by CXB boost (90 Gy in 3 fractions over 4 weeks). Patients were assessed at 14, 20 and 24 weeks from the start of treatment. Watch and wait management was adopted for patients who achieved a clinical complete response (cCR) at 24 weeks following treatment. Either local excision (LE) or TME surgery was offered for residual disease or local regrowth, according to patient and surgeon preference. Surgical morbidity and mortality were recorded prospectively.

Results

Between July 2015 and June 2020, 148 patients were randomised of which 141 were evaluable in March 2022. At median follow‐up of 38.2 months (range: 34.2–42.5), surgery was performed for 66 (47%) patients. A total of 27 (20%) patients had local excision and 39 (29%) had TME surgery, 22/39 (56%) underwent anterior resection and 17/39 (44%) underwent abdominoperineal excision of the rectum. The R0 resection rate was 87%. There were no deaths, and six patients (15%) had Clavien‐Dindo IIIb complications. Whilst there was a statistically significant decrease in the TME rate following CXB boost (HR 0.38, 95% CI: 0.19–0.74, p = 0.00419) there was no difference in surgical outcomes between patients who received EBRT and CXB boost.

Conclusion

Dose escalation can facilitate nonsurgical treatment for cT2‐3 rectal cancer patients who are fit but wish to avoid TME surgery and stoma. If TME surgery is required, then it can be performed safely and effectively.

Subjects

MeSH terms (MEDLINE)

Rectal NeoplasmsAdenocarcinomaHumansOrgan PreservationNeoadjuvant TherapyChemoradiotherapyTreatment OutcomeNeoplasm Recurrence, Local

Author keywords

contact X-ray brachytherapyneoadjuvant treatmentorgan preservationrectal cancer

Authors and institutions

  • Clatterbridge Cancer Centre, Liverpool, UK.
  • Department of Surgery and Cancer, Imperial College London, London, UK.
  • Department of Colorectal Surgery, The Cumberland Infirmary, Carlisle, UK.
  • ORLAM Lyon-Villeurbanne-Mâcon, Villeurbanne, France.
  • Departement of Epidemiology, Biostatistic, and Health Data, Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.
  • Department of Radiation Oncology, Saint-Priest-en-Jarez, France.

ORCID profiles: Arthur Sun Myint

Cite

APA

Sun Myint, A., Rao, C., Barbet, N., Thamphya, B., Pace-Loscos, T., Schiappa, R., Magné, N., Martel-Lafay, I., Mineur, L., Deberne, M., Zilli, T., Dhadda, A., & Gerard, J. P. (2023). The safety and efficacy of total mesorectal excision ( TME ) surgery following dose‐escalation: Surgical outcomes from the organ preservation in early rectal adenocarcinoma ( OPERA ) trial, a European multicentre phase 3 randomised trial ( NCT02505750 ). Colorectal Disease. https://doi.org/10.1111/codi.16773

Vancouver

Sun Myint A, Rao C, Barbet N, Thamphya B, Pace-Loscos T, Schiappa R, et al. The safety and efficacy of total mesorectal excision ( TME ) surgery following dose‐escalation: Surgical outcomes from the organ preservation in early rectal adenocarcinoma ( OPERA ) trial, a European multicentre phase 3 randomised trial ( NCT02505750 ). Colorectal Disease. 2023. doi:10.1111/codi.16773

BibTeX
@article{SunMyint2023,
  author = {Sun Myint, Arthur and Rao, Christopher and Barbet, Nicolas and Thamphya, Brice and Pace-Loscos, Tanguy and Schiappa, Renaud and Magné, Nicolas and Martel-Lafay, Isabelle and Mineur, Laurent and Deberne, Melanie and Zilli, Thomas and Dhadda, Amandeep and Gerard, Jean Pierre},
  title = {The safety and efficacy of total mesorectal excision ( TME ) surgery following dose‐escalation: Surgical outcomes from the organ preservation in early rectal adenocarcinoma ( OPERA ) trial, a European multicentre phase 3 randomised trial ( NCT02505750 )},
  journal = {Colorectal Disease},
  year = {2023},
  doi = {10.1111/codi.16773}
}
Start for free →